In the early 1990s, serious concerns about the dangers associated with genetic engineering arose after an incident pertaining to the use of certain genetically altered mice in experiments involving a highly infectious disease. In the wake of these concerns, the National Institute of Allergy and Infectious Diseases held a conference to discuss the level of safety that should be followed in laboratories involved in such research. Those involved in the conference included the researchers themselves, certain biosafety experts, representatives from organizations involved in or planning to be involved in similar research, and governmental representatives from the Centers for Disease Control, the National Institutes of Health, and the Food and Drug Administration. Would this type of situation be appropriate for a reg-neg approach? Explain. Might a science court handle this type of situation even better than an agency’s reg-neg procedure? Explain.